High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
The results of high-dose chemotherapy with melphalan or melphalan (carmustine) etoposide for 66 consecutive patients with relapsed or resistant Hodgkin's disease are described. 55 patients were evaluable for response and 22% of these achieved complete remission and 59% partial remission. The actuarial survival at 2 years was 45% and the principal factors determining survival were the sensitivity of the disease to therapy given before high-dose chemotherapy and the type of treatment received. Intensive chemotherapy with autologous bone marrow transplantation can produce long-term survivors among patients for whom long-term survival would otherwise be improbable. However, this treatment remains toxic with an uncertain place in management.
Harding
M
M
Yorkshire Cancer Research Campaign, Institute for Cancer Studies, St. James's University Hospital, U.K.
Selby
P
P
Gore
M
M
Perren
T
T
Treleavan
J
J
Mansi
J
J
Zulian
G
G
Milan
S
S
Meldrum
M
M
Viner
C
C
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous
D005047:Etoposide; D008558:Melphalan; D002330:Carmustine